Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca CEO Defends Global Impact Of Its COVID-19 Vaccine

Maligned Vaccine Is Biggest Contributor To India, COVAX

Executive Summary

Pascal Soriot said AZ employees should be proud of the COVID-19 vaccine achievements so far, but conceded that manufacturing output would continue to lag.

You may also be interested in...



Coronavirus Update: Moderna Donates More Doses, Booster Shot Shows Efficacy

Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

Alexion Deal Adds Up For AstraZeneca's Rare Disease Specialist CFO

The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel